IES4 Antibody

What is IES4 and what role does it play in cellular processes?

IES4 (Ino Eighty Subunit 4) functions as a critical subunit of the INO80 chromatin remodeling complex. The protein plays a significant role in DNA damage response pathways, primarily through its phosphorylation state. When phosphorylated by Mec1/Tel1 kinases in response to DNA damage, IES4 facilitates interactions between the INO80 complex and the checkpoint kinase Rad53 . These interactions are mediated specifically through the Rad53-N-FHA domain, which recognizes the phosphorylated form of IES4 . This molecular interaction contributes to the activation of Rad53, a central mediator in DNA damage checkpoint responses. Studies utilizing INO80 complexes from cells treated with DNA-damaging agents such as MMS (methyl methanesulfonate) have demonstrated enhanced interactions between phosphorylated IES4 and Rad53, suggesting that this phosphorylation-dependent interaction is dynamically regulated during cellular stress responses .

What are the recommended applications for IES4 antibodies in research?

IES4 antibodies are valuable tools for multiple research applications investigating chromatin remodeling, DNA damage responses, and cell cycle checkpoint activation. Primary applications include:

• Western blotting to detect IES4 protein levels and phosphorylation states in cellular extracts

• Immunoprecipitation assays to isolate INO80 complexes and study protein-protein interactions

• Chromatin immunoprecipitation (ChIP) to investigate INO80 complex recruitment to chromatin

• Immunofluorescence microscopy to visualize IES4 localization during DNA damage response

For optimal results, researchers should select antibodies validated specifically for their application of interest. When studying phosphorylation-dependent interactions, phospho-specific antibodies that recognize particular phosphorylated residues of IES4 are recommended . These specialized antibodies can differentiate between basal phosphorylation states and the hyperphosphorylated forms that occur after DNA damage, providing critical insights into the activation status of this pathway.

How should researchers validate IES4 antibody specificity?

Thorough validation of IES4 antibodies is essential for generating reliable research data. A comprehensive validation protocol should include:

• Knockout/knockdown controls: Testing antibody reactivity in samples where IES4 has been deleted (Δies4 mutant) or depleted through RNAi provides the most stringent specificity control . The absence of signal in these negative controls confirms antibody specificity.

• Phosphorylation-state controls: For phospho-specific IES4 antibodies, comparison between untreated samples and those treated with DNA-damaging agents like MMS should show differential reactivity . Additionally, samples from phospho-blocking mutants (e.g., ies4 (S:A5) where serine residues are replaced with alanine) should show reduced reactivity with phospho-specific antibodies.

• Cross-reactivity assessment: Testing against related INO80 complex subunits ensures the antibody does not recognize structurally similar proteins.

• Peptide competition assays: Pre-incubating antibodies with the specific peptide used for immunization should block signal in subsequent detection assays if the antibody is specific.

Development of antibodies requires extensive screening to ensure consistent performance across applications. Similar validation approaches have been successfully employed for other research antibodies, resulting in highly specific reagents with minimal cross-reactivity .

What are the optimal conditions for using IES4 antibodies in Western blotting?

Successful Western blotting with IES4 antibodies requires careful optimization of several parameters:

• Sample preparation: For detecting phosphorylated IES4, samples should be prepared with phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, and β-glycerophosphate) to preserve phosphorylation status. Cell lysis should be performed using buffers containing detergents suitable for nuclear protein extraction, such as RIPA or NP-40 supplemented with protease inhibitors.

• Gel selection: Resolution of phosphorylated versus non-phosphorylated IES4 requires 8-10% polyacrylamide gels, as the phosphorylated forms typically migrate slower, creating a characteristic upward smear pattern similar to that observed with activated Rad53 .

• Transfer conditions: For optimal transfer of nuclear proteins like IES4, wet transfer systems using 20% methanol or semidry systems with increased transfer time are recommended.

• Blocking and antibody incubation: 5% BSA in TBST is preferable to milk for phospho-specific antibodies, as milk contains phosphoproteins that may interfere with detection. Primary antibody dilutions typically range from 1:500 to 1:2000, with overnight incubation at 4°C yielding the best signal-to-noise ratio.

• Detection system: Enhanced chemiluminescence (ECL) systems are suitable for standard detection, while fluorescent secondary antibodies may provide better quantitative analysis for phosphorylation studies.

These recommendations are based on protocols that have been successfully applied to studying phosphorylation-dependent interactions in similar experimental systems, such as those used for analyzing Rad53 activation .

How can researchers optimize immunoprecipitation protocols for studying IES4 interactions?

Immunoprecipitation (IP) experiments with IES4 antibodies require specific considerations to maintain protein-protein interactions within the INO80 complex:

• Cell treatment: To study DNA damage-induced interactions, treat cells with appropriate DNA-damaging agents (e.g., 0.03% MMS for 2 hours) before harvesting .

• Lysis conditions: Use gentle lysis buffers (e.g., 20 mM HEPES pH 7.5, 100 mM KCl, 0.5% NP-40, 10% glycerol) supplemented with both protease and phosphatase inhibitors to preserve complex integrity and phosphorylation status.

• Antibody coupling: For reproducible results, covalently couple IES4 antibodies to protein A/G beads using crosslinkers like dimethyl pimelimidate (DMP) to prevent antibody leaching during elution.

• Washing stringency: Adjust salt concentration in wash buffers (typically 100-250 mM KCl) to maintain specific interactions while reducing background. For detecting transient or weak interactions, such as those between phospho-IES4 and Rad53-N-FHA domain, lower stringency washes are recommended .

• Elution strategies: For phosphorylation-dependent interactions, competitive elution with phosphopeptides can provide specificity confirmation. Alternatively, standard elution using SDS sample buffer is effective for subsequent Western blot analysis.

• Controls: Include IgG control, input sample, and where possible, samples from Δies4 mutants or phospho-blocking mutants to validate specificity of detected interactions .

This approach has successfully demonstrated the phosphorylation-dependent interaction between the INO80 complex and Rad53, revealing stronger interaction with INO80 purified after MMS treatment compared to untreated controls .

What technical challenges might researchers encounter when using IES4 antibodies in ChIP assays?

Chromatin immunoprecipitation (ChIP) with IES4 antibodies presents several technical challenges that researchers should anticipate:

• Chromatin preparation: Due to INO80's role in chromatin remodeling, optimal crosslinking conditions (typically 1% formaldehyde for 10-15 minutes) are critical. Insufficient crosslinking may fail to capture transient interactions, while excessive crosslinking can reduce antibody accessibility.

• Sonication parameters: INO80 complexes associate with nucleosomes, requiring optimization of sonication conditions to generate appropriate chromatin fragment sizes (200-500 bp) without disrupting protein complexes.

• Antibody specificity: ChIP applications are particularly sensitive to antibody cross-reactivity. Thorough validation using IES4 knockout or knockdown controls is essential before interpreting ChIP data .

• Background signal: IES4 antibodies may generate higher background signals in ChIP experiments compared to other applications. Implementation of stringent washing steps and inclusion of appropriate negative controls (IgG and knockout/knockdown samples) helps distinguish specific signals from background.

• Temporal dynamics: When studying DNA damage responses, the timing of sample collection after damage induction significantly impacts results. Time-course experiments are recommended to capture the dynamic nature of IES4 phosphorylation and INO80 complex recruitment.

Similar challenges have been addressed in studies of other chromatin-associated factors, where optimization of fixation conditions and sonication parameters significantly improved signal-to-noise ratios and reproducibility .

How do phosphorylation patterns of IES4 influence antibody selection for different research questions?

The phosphorylation status of IES4 is dynamically regulated during DNA damage responses, requiring careful antibody selection based on specific research objectives:

• Basal versus damage-induced phosphorylation: IES4 exhibits low basal phosphorylation under normal conditions, with significantly enhanced phosphorylation following DNA damage . Researchers investigating damage-specific pathways should select phospho-specific antibodies that preferentially recognize the hyperphosphorylated form.

• Site-specific phosphorylation: Multiple serine residues in IES4 can be phosphorylated, potentially with different functional outcomes. Antibodies recognizing specific phosphorylation sites enable differentiation between these various modified forms. Phosphorylation site mapping studies with mass spectrometry can guide selection of appropriate site-specific antibodies.

• Temporal dynamics: The kinetics of IES4 phosphorylation following DNA damage show specific patterns, with initial phosphorylation occurring rapidly. Time-course studies require antibodies that maintain consistent affinity across different phosphorylation states to accurately quantify temporal changes.

• Cross-species research: When conducting comparative studies across model organisms, researchers should verify epitope conservation, as phosphorylation sites may not be conserved despite functional conservation of the IES4 protein.

For studies specifically examining the interaction between phospho-IES4 and Rad53, antibodies recognizing phosphorylated residues that mediate this interaction have proven most informative . Similar approaches have been applied successfully in characterizing phosphorylation-dependent interactions in other signaling pathways .

What strategies can researchers employ to study IES4 phosphorylation-dependent interactions in vivo?

Investigating phosphorylation-dependent IES4 interactions in vivo presents unique challenges that can be addressed through several specialized approaches:

• Proximity-based labeling: Techniques such as BioID or APEX2 fusion to IES4 enable identification of proteins that interact transiently or weakly in a phosphorylation-dependent manner. These approaches involve expressing IES4 fused to a biotin ligase or peroxidase, which biotinylates neighboring proteins for subsequent purification and identification.

• FRET-based biosensors: Developing fluorescence resonance energy transfer (FRET) sensors with IES4 and potential interacting partners like Rad53 allows real-time visualization of these interactions in living cells following DNA damage induction.

• Phosphomimetic and phospho-blocking mutants: Generating IES4 variants where phosphorylated serine residues are replaced with either aspartic acid (phosphomimetic) or alanine (phospho-blocking) enables functional studies of phosphorylation-dependent interactions . These mutants can be expressed in Δies4 backgrounds to evaluate the specific contribution of phosphorylation to protein interactions.

• Split reporter systems: Techniques like bimolecular fluorescence complementation (BiFC) or split luciferase assays can visualize interactions between IES4 and binding partners in intact cells, potentially revealing the subcellular localization of these interactions during DNA damage responses.

• In situ proximity ligation assay (PLA): This technique enables visualization of protein-protein interactions at endogenous expression levels in fixed cells, allowing quantification of interactions between phosphorylated IES4 and partners like Rad53 in different cellular compartments.

These approaches complement traditional biochemical methods like co-immunoprecipitation, which has successfully demonstrated enhanced interaction between phosphorylated IES4 and Rad53-N-FHA domain following DNA damage .

What are the most effective methods for quantifying IES4 phosphorylation levels in different experimental conditions?

Accurate quantification of IES4 phosphorylation requires methods that can distinguish between different phosphorylation states and provide reliable quantitative data:

• Phos-tag™ SDS-PAGE: This specialized electrophoresis technique incorporates manganese-Phos-tag molecules into polyacrylamide gels to specifically retard the migration of phosphorylated proteins. It enables separation of IES4 based on the number and position of phosphate groups, visualizing multiple phosphorylation states as distinct bands.

• Mass spectrometry approaches:

  • Selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) provide highly sensitive, targeted quantification of specific phosphopeptides from IES4.

  • Parallel reaction monitoring (PRM) offers improved selectivity for analyzing complex phosphorylation patterns.

  • Stable isotope labeling with amino acids in cell culture (SILAC) enables comparative analysis of phosphorylation changes across different conditions.

• Phospho-specific antibody arrays: Custom antibody arrays using multiple phospho-specific IES4 antibodies can simultaneously measure different phosphorylation sites, providing a phosphorylation profile across experimental conditions.

• Capillary electrophoresis: This technique offers high-resolution separation of different phosphorylated forms with minimal sample requirements, ideal for analyzing limited samples or single-cell studies.

• Fluorescence polarization assays: For recombinant IES4 proteins, in vitro kinase assays followed by fluorescence polarization can quantify phosphorylation kinetics using fluorescently-labeled phospho-specific antibodies.

When applying these methods, researchers have observed distinct patterns of IES4 phosphorylation following DNA damage, with increased phosphorylation correlating with enhanced interactions with Rad53 . Similar quantitative approaches have been successfully employed to track phosphorylation dynamics in other protein systems .

How should researchers interpret unexpected IES4 antibody signals in Western blots?

Unexpected patterns in Western blots with IES4 antibodies require systematic troubleshooting and careful interpretation:

• Multiple bands: The appearance of multiple bands may represent:

  • Different phosphorylation states of IES4, particularly following DNA damage (characteristic upward smear)

  • Alternative splice variants or post-translationally modified forms

  • Proteolytic fragments due to incomplete protease inhibition during sample preparation

  • Non-specific cross-reactivity with related proteins

• Absence of expected signal:

  • Verify sample preparation protocols, particularly for nuclear proteins which may require specialized extraction methods

  • Confirm antibody compatibility with denaturation conditions; some epitopes may be sensitive to reducing agents or heat denaturation

  • Test alternative blocking agents; phospho-specific antibodies often perform better with BSA than milk-based blocking solutions

  • Consider epitope masking due to protein-protein interactions or post-translational modifications

• Inconsistent signal intensity:

  • Standardize protein loading using multiple loading controls (e.g., total protein staining plus housekeeping proteins)

  • Account for cell cycle-dependent expression or modification of IES4

  • Consider sample-specific phosphatase activity that may affect phosphorylated IES4 detection

• High background:

  • Increase washing stringency gradually while monitoring specific signal retention

  • Test alternative blocking agents to reduce non-specific binding

  • Reduce primary antibody concentration or incubation time

For phosphorylation-specific detection, comparing samples treated with phosphatase to untreated controls can confirm whether multiple bands represent phosphorylated forms. Additionally, using samples from phospho-blocking mutants (ies4 (S:A5)) as negative controls helps validate phospho-specific signals .

What approaches can address cross-reactivity issues with IES4 antibodies?

Cross-reactivity challenges with IES4 antibodies can significantly impact data interpretation but can be systematically addressed through several approaches:

• Epitope mapping and antibody redesign: Detailed mapping of the antibody binding epitope can identify regions unique to IES4 versus other INO80 complex subunits. This information enables rational redesign of antibodies targeting unique epitopes, similar to approaches used for engineering highly specific antibodies against closely related targets .

• Subtraction strategies: Pre-adsorption of antibodies with recombinant proteins related to IES4 can remove cross-reactive antibodies from polyclonal preparations. This approach has been successfully applied to improve specificity in other complex protein systems .

• Genetic validation: Data from Δies4 mutants provides the gold standard for specificity confirmation . Any signal detected in knockout samples indicates cross-reactivity that must be accounted for in experimental interpretations.

• Orthogonal detection methods: Confirming key findings using multiple detection methods reduces the impact of antibody-specific artifacts. For instance, mass spectrometry-based detection of IES4 and its interacting partners can complement antibody-based detection.

• Affinity purification: For polyclonal antibodies, affinity purification against the specific immunizing peptide can enrich for antibodies recognizing the intended epitope while removing cross-reactive antibodies.

• Competitive binding assays: Performing Western blots or immunoprecipitations in the presence of excess IES4-specific peptide can confirm signal specificity; true IES4 signals should be competitively inhibited while cross-reactive signals may remain.

These approaches have proven effective in developing highly specific antibodies against challenging targets, including cytokines and their receptors where cross-reactivity must be minimized for reliable research outcomes .

What control experiments are essential when studying phosphorylation-dependent interactions of IES4?

When investigating phosphorylation-dependent interactions of IES4, particularly with partners like Rad53, several critical control experiments are necessary to ensure data validity:

• Phosphatase treatment controls: Treating samples with lambda phosphatase prior to immunoprecipitation should abolish or significantly reduce interactions that are truly phosphorylation-dependent . This control distinguishes phosphorylation-dependent interactions from those mediated by other mechanisms.

• Phospho-mimetic and phospho-blocking mutants: Comparing interaction patterns between wild-type IES4, phospho-blocking mutants (ies4 (S:A5)), and phospho-mimetic mutants (S:D or S:E substitutions) provides genetic evidence for phosphorylation dependency . These mutants serve as critical negative and positive controls, respectively.

• Domain mutant controls: For interactions mediated by specific domains, such as the Rad53-N-FHA domain, parallel experiments with domain-inactivating mutants are essential . For example, mutations in the FHA domain that disrupt phosphopeptide binding should abolish interaction with phosphorylated IES4.

• Time-course analysis: Temporal correlation between IES4 phosphorylation kinetics and interaction strength supports causality. This control is particularly important when studying DNA damage-induced interactions, where both phosphorylation and interaction patterns change dynamically over time.

• Specificity controls for binding partners: When studying specific interactions (e.g., with Rad53), parallel experiments with related proteins containing similar domains help establish interaction specificity .

• In vitro reconstitution: Demonstrating that purified, phosphorylated IES4 (or phosphopeptides derived from IES4) can directly bind to purified interaction partners provides strong evidence for direct, phosphorylation-dependent interactions.

These control experiments have successfully validated the phosphorylation-dependent interaction between IES4 and Rad53, showing reduced interaction with INO80 complex purified from Δies4 or phospho-blocking ies4 (S:A5) mutants compared to wild-type .

How do different antibody formats affect experimental design when studying IES4?

The format of IES4 antibodies significantly impacts experimental design and interpretation, requiring format-specific optimization:

When selecting antibody formats for IES4 studies, researchers should consider that phosphorylation-specific interactions, such as those between phospho-IES4 and the Rad53-N-FHA domain, may be best detected using antibody formats that minimize steric hindrance around phosphorylation sites . Development of format-specific protocols has been crucial for successful antibody engineering in other research contexts .

What considerations are important when developing new IES4 antibodies for specific research applications?

Developing new IES4 antibodies for specialized research applications requires strategic planning across multiple dimensions:

• Epitope selection considerations:

  • Conservation analysis: For cross-species applications, target epitopes conserved across relevant species

  • Structural accessibility: Select epitopes likely to be surface-exposed in native protein conformation

  • Post-translational modification sites: For phospho-specific antibodies, target known phosphorylation sites while ensuring surrounding sequence contributes to specificity

  • Functional domains: Target epitopes away from protein-protein interaction surfaces if detecting protein complexes is the goal

• Immunization strategies:

  • Peptide versus recombinant protein: Peptide immunization enables precise epitope targeting but may yield antibodies that poorly recognize native protein. Recombinant protein immunization typically produces antibodies recognizing multiple epitopes.

  • Carrier protein selection: Choice of carrier protein impacts immunogenicity and potential cross-reactivity

  • Adjuvant optimization: Different adjuvants can bias immune responses toward specific antibody isotypes or epitope preferences

• Screening methodology:

  • Multi-application screening: Test candidate antibodies across all intended applications early in development

  • Counter-screening: Include Δies4 samples to identify and eliminate cross-reactive clones

  • Affinity determination: Quantify binding affinities (KD values) using methods like bio-layer interferometry to select high-affinity antibodies

• Production format selection:

  • Expression system: Different expression systems (bacterial, mammalian, insect) impact glycosylation and folding

  • Purification strategy: Affinity purification methods affect antibody functionality and batch consistency

  • Antibody engineering: Consider humanization for therapeutic applications or Fc engineering to reduce background in specific applications

These considerations have been successfully applied in developing highly specific antibodies for challenging targets, including receptor-targeted antibodies with picomolar affinities (KD ≈ 178 pM) and minimal cross-reactivity to related proteins .

How can computational approaches improve IES4 antibody design and application?

Computational methods significantly enhance both IES4 antibody design and experimental application planning:

• Epitope prediction and optimization:

  • B-cell epitope prediction algorithms identify regions likely to generate strong antibody responses

  • Structural modeling predicts epitope accessibility in native protein conformation

  • Conservation analysis across species identifies evolutionarily constrained regions that may serve as stable epitopes

  • Post-translational modification prediction tools identify potential phosphorylation sites for phospho-specific antibody development

• Antibody sequence optimization:

  • Complementarity-determining region (CDR) engineering can enhance affinity and specificity through computational design approaches similar to those used for engineered antibodies against other targets

  • Developability assessment algorithms predict potential manufacturing and stability issues before experimental production

  • Germline humanization approaches reduce potential immunogenicity while maintaining binding properties

• Experimental design enhancement:

  • Molecular dynamics simulations predict antibody-antigen interaction stability under different buffer conditions

  • Epitope mapping algorithms using peptide array data guide optimal antibody selection for specific applications

  • Cross-reactivity prediction tools identify potential off-target binding based on epitope sequence similarity across the proteome

• Data analysis improvements:

  • Image analysis algorithms enhance quantification of Western blot and immunofluorescence data

  • Interaction network modeling places IES4 interactions in broader biological context

  • Binding kinetics modeling predicts optimal antibody concentration and incubation times for different applications

These computational approaches have been successfully implemented in antibody development pipelines, resulting in antibodies with improved specificity, affinity, and application performance . For example, in silico screening of large antibody variant libraries has enabled selection of candidates with optimal biophysical properties, significantly accelerating the antibody development process .

What are the emerging trends in IES4 antibody development and application?

The field of IES4 antibody development continues to evolve, with several emerging trends that promise to enhance research capabilities:

• Multi-specific antibody formats that simultaneously recognize IES4 and interaction partners like Rad53 are being developed to better capture and study transient protein complexes formed during DNA damage responses. These formats potentially offer superior detection of context-specific interactions compared to conventional antibodies.

• Intracellular antibody fragments (intrabodies) that can be expressed within living cells represent an emerging approach for tracking endogenous IES4 dynamics and interactions in real-time. This technology circumvents limitations of cell permeabilization required for conventional antibody application.

• Proximity-based detection systems combining IES4 antibodies with enzymatic reporters (HRP, APEX2) enable more sensitive detection of low-abundance complexes and transient interactions in their native cellular context, potentially revealing previously undetectable interactions.

• Quantitative super-resolution microscopy applications using site-specific IES4 antibodies are advancing our understanding of INO80 complex spatial organization during DNA damage responses, providing nanoscale resolution of complex assembly and disassembly.

• Automated high-throughput screening platforms for antibody specificity are improving validation standards, particularly for phospho-specific antibodies where cross-reactivity has been a persistent challenge .

These emerging approaches build upon established methodologies while addressing previous technical limitations, similar to advances seen in other antibody development fields . The integration of computational design with experimental validation continues to accelerate development cycles and improve antibody performance metrics.

How can researchers effectively troubleshoot complex experimental issues with IES4 antibodies?

When facing complex experimental challenges with IES4 antibodies, a systematic troubleshooting approach is essential:

• Establish a decision tree for common issues:

  • For weak or absent signals, systematically evaluate: epitope accessibility, antibody concentration, incubation conditions, detection system sensitivity, and sample preparation

  • For high background or non-specific signals, sequentially adjust: blocking conditions, washing stringency, antibody dilution, and detection system parameters

  • For inconsistent results between experiments, examine: lot-to-lot antibody variation, sample handling differences, and protocol deviations

• Implement parallel validation approaches:

  • Simultaneously test multiple antibodies targeting different IES4 epitopes

  • Compare results across complementary techniques (e.g., Western blot, immunoprecipitation, mass spectrometry)

  • Include genetic controls (Δies4 and phospho-mutants) in parallel experiments

• Conduct systematic parameter optimization:

  • Use design-of-experiments (DOE) methodology to efficiently test multiple variables simultaneously

  • Establish quantitative metrics for assay performance to objectively compare conditions

  • Develop positive and negative control samples with known IES4 status for benchmark testing

• Address phosphorylation-specific challenges:

  • Implement specialized phosphoprotein preservation protocols during sample preparation

  • Use phosphatase inhibitor cocktails optimized for nuclear phosphoproteins

  • Consider phosphorylation dynamics in experimental timing, particularly after DNA damage induction

This systematic approach has proven effective in resolving complex experimental challenges in related research areas, including studies of other phosphorylation-dependent interactions in DNA damage signaling pathways .

What future directions will advance IES4 antibody technologies in research?

Several promising future directions will likely transform IES4 antibody technologies and their research applications:

• Integration with CRISPR-based technologies will enable simultaneous genetic manipulation and antibody-based detection, allowing researchers to study the consequences of IES4 modifications in real-time within the same experimental system.

• Development of degradation-targeting antibody conjugates (e.g., PROTACs or ABTACS) specific to IES4 will provide precise temporal control over protein degradation, enabling functional studies with unprecedented temporal resolution compared to genetic knockout approaches.

• Single-cell antibody-based proteomics will reveal cell-to-cell variation in IES4 phosphorylation and interaction patterns within heterogeneous cell populations, potentially uncovering subpopulation-specific responses to DNA damage that are masked in bulk analyses.

• Machine learning algorithms for antibody optimization will accelerate development of application-specific IES4 antibodies by predicting sequence modifications that enhance specificity, stability, and performance in specific experimental contexts.

• Synthetic biology approaches combining antibody-based detection with engineered signaling outputs will create cellular sensors for IES4 status, enabling real-time monitoring of DNA damage responses in living systems.